NUVB
The table below shows Nuvation Bio Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$173.43M | -$130.41M | -$68.00M | -$96.11M | -$68.19M | -$36.53M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $99.52M | $122.70M | $8.92M | $63.46M | -$454.67M | -$70.32M |
| Dividends paid | - | - | - | - | - | - |
Nuvation Bio Inc. reported operating cash flow of -$173.43M for fiscal year 2025. That is down 33.0% from -$130.41M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$36.53M (FY 2020) to -$173.43M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $202.53M | $331.00K | $628.00K | $1.33M | $625.53M | $133.13M |